ETHIZIA Hemostatic Patch
ETHICON, Inc. · Decision date Jan 28, 2026
What did the FDA approve?
FDA records P240035/S003 as a supplement to PMA P240035, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jan 28, 2026.
FDA approval order statement
the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240035
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Jan 28, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P240035/S003
- Regulatory pathway
- PMA supplement
- Applicant
- ETHICON, Inc.
- Product code
- SGV
- Decision code
- APPR
- Decision date
- Jan 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, collagen with polymeric additives.
- Applicant
- ETHICON, Inc.
- Product code
- SGV
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240035. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240035 · Original PMA
ETHIZIA
P240035/S003 received
Application receipt date recorded by FDA.
P240035/S001 · Related supplement
ETHIZIA Hemostatic Patch
P240035/S003 · FDA decision
Normal 180 Day Track No User Fee
P240035/S006 · Related supplement
ETHIZIA Hemostatic Patch
P240035/S005 · Related supplement
ETHIZIA Hemostatic Patch
P240035/S002 · Related supplement
ETHIZIA Hemostatic Patch
P240035/S004 · Related supplement
ETHIZIA Hemostatic Patch
Timeline entries are records held by MedtechLedger for P240035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ETHIZIAP240035 | ETHICON, Inc. | PMA approval | Dec 15, 2025 | FDA |
ETHIZIA Hemostatic PatchP240035/S001 | ETHICON, Inc. | PMA supplement | Jan 22, 2026 | FDA |
ETHIZIA Hemostatic PatchP240035/S006 | ETHICON, Inc. | PMA supplement | Feb 24, 2026 | FDA |
ETHIZIA Hemostatic PatchP240035/S005 | ETHICON, Inc. | PMA supplement | Feb 26, 2026 | FDA |
ETHIZIA Hemostatic PatchP240035/S002 | ETHICON, Inc. | PMA supplement | Jun 25, 2026 | FDA |
ETHIZIA Hemostatic PatchP240035/S004 | ETHICON, Inc. | PMA supplement | Aug 27, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
ETHICON, Inc.
- Headquarters
- Not reported
- Brand website
- ethicon.com
- FDA applicant address
- 1000 Rte. 202, Raritan, NJ, 08869
Sources and methodology
- Original FDA record: P240035/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
